{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/eric-s-winer/", "hostname": "dana-farber.org", "description": "Eric S. Winer, MD - Medical Oncology. Dr. Winer received his MD from The University of North Carolina School of Medicine in 1999. He completed his residency in Internal Medicine at Tufts Medical Center. He remained at Tufts Medical Center for a clinical hematology/oncology fellowship, which he completed in 2005.", "sitename": "Eric S. Winer, MD - Dana-Farber Cancer Institute", "date": "2023-01-01", "cleaned_text": "Survival in male breast cancer over the past 3 decades. J Natl Cancer Inst. 2023 04 11; 10-year analysis of the open-label, phase 2 Oncol. 2023 03; 24(3):273-285. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36858723) Tucatinib vs Placebo, Both in Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Oncol. 2023 02 01; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36454580) Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clin 04; 29(1):174-182. View to \"Tucatinib versus capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases overall survival analysis\": Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Enrolled HER2-negative breast cancer. 197(2):319-331. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36401732) Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. Cancer Res. 2022 10 17; 82(20):3673-3686. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35950920) in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36252998) Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer. 2022 Nov Aug Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled Cancer J. 2022 07 19; 12(7):110. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35853853) Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Multidimensional Molecular and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast 31; View following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast 1b Clinical with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. Cancer Res. 2022 04 14; 28(8):1493-1499. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35149538) at a II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Breast plus Letrozole in Advanced Cancer. N 2022 03 10; 386(10):942-950. View adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled Feb 16; 8(1):18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35173164) Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Res Treat. 2022 Feb; 192(1):201-210. Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in 40(12):1323-1334. Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative 40(5):449-458. View and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases final overall survival analysis. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34954044) Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase KAITLIN View in: Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Inst. DNA With impact of exercise and mind-body prehabilitation interventions on physical and psychological outcomes in women undergoing breast cancer surgery. Support Care Cancer. 2022 Mar; 30(3):2027-2036. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34648061) Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34472667) Molecular eribulin and pembrolizumab in hormone receptor-positive metastatic 21; 12(1):5563. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34548479) 2021 11 10; 39(32):3648-3649. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34506210) The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 09 04; cancer: a phase II Cancer. 2021 Aug 25; 7(1):110. II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. Breast Cancer Res Treat. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33523233) to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305. JOSD1 as a novel targeted Leukemia. 2022 01; 36(1):210-220. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34326465) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer in combination with trastuzumab ATEMPT Trial). Res Treat. 2021 Aug; 189(1):103-110. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34120223) The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ With for Stage I HER2-Positive Breast Cancer (ATEMPT): A 39(21):2375-2385. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34077270) Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J of rapid versus late relapse in triple negative breast cancer. BMC Cancer. 2021 May 18; 21(1):568. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34006255) Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33978307) Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist. 2021 08; 26(8):685-693. View in: of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical 10; 11(10):2474-2487. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33941592) Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33893907) Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33507222) A 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33676601) Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33590387) with weekly paclitaxel for the adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33460574) Perceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 04 15; 127(8):1208-1219. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33320362) Genomic Characterization Res. 2021 02 15; 27(4):1105-1118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33293374) Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with 2021 02 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33257427) Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33256829) Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2021 Feb; 186(1):157-165. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33150547) PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast 2020 11 02; 22(1):120. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33138866) TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Oncol. 38(35):4184-4193. in: Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, Breast View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32880602) A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 12 01; 26(23):6149-6157. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32988969) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020 12; 31(12):1623-1649. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32979513) Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32939592) A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. Ann Oncol. 2020 12; 31(12):1704-1708. View in: versus paclitaxel in triple-negative breast cancer: evaluating and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32723837) Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab. Clin Cancer Res. 2020 26(18):4911-4920. View in: Therapy for HER2-Positive Metastatic 18; 382(25):e98. View Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Clin Oncol. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32468955) dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. 2020 09; 31(9):1231-1239. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32461105) The Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Cancer Discov. 2020 08; 10(8):1174-1193. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32404308) Barriers to Clinical Trial Accrual: of Community-Based Clin Breast Paclitaxel Regimen: 07 20; 38(21):2390-2397. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32330102) Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer in Germline BRCA Carriers With HER2-Negative 10; 38(14):1539-1548. trial of atezolizumab plus nab-paclitaxel in metastatic View Reversion and non-reversion mechanisms of to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic 2020 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32245699) Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. 06 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32019858) A Phase II Study in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic 06; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32113750) The combination of FLT3 and kinase inhibitors is toxic to leukaemia cells with CBL mutations. J Cell Mol Med. 24(3):2145-2156. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31943762) Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Oncol. 2020 03; 02 382(7):597-609. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31825569) Prognostic Impact of the 21-Gene Assay Among Young Women With Node-Negative and advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase trial. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31786121) Identifying ERBB2 Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32923853) Updated a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2019 11 01; 30(11):1842. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31407010) Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31373601) A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123. View in: Reply to 11 01; 37(31):2954-2955. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31518173) A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31250880) Metastases: Translational Breast Research Consortium Clin 20(2):145-151.e2. View in: Subsets of Metastatic Cancer. 2020 02; 20(1):e20-e26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31631016) Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 09 10; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31339827) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31277699) Evaluating the addition of bevacizumab endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31276981) Ribociclib Plus Trastuzumab Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer. 2019 12; 19(6):399-404. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31235441) The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy. Clin Cancer Res. 2019 08 01; 25(15):4644-4655. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31061067) Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study. Clin Cancer Res. 2019 Sep 01; 25(17):5398-5406. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31018921) recurrence in women with node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31004299) Seven-Year for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Oncol. 2019 08 01; 37(22):1868-1875. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30939096) The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019 04 dose-expansion phase II of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain breast cancer: cohort A of the phase II cancer: cohort B of the Ann Oncol. 2019 03 01; 30(3):405-411. Letrozole Plus Alpelisib for Hormone Receptor-Positive, Epidermal Growth Factor Receptor 2-Negative Cancer Phase II Trial Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast 20; 37(9):714-722. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30721110) Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. Ann Oncol. 2019 01 Acquired HER2 cancer to 2019 Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist. 2019 07; 24(7):e441-e449. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30518616) Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. 10; in Advanced Cancer. Med. 2018 11 29; 379(22):2108-2121. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30345906) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29733336) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30083595) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018 08 01; 29(8):1634-1657. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30032243) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30037817) CDK4/6 inhibition Med 10:1758835918786451. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30038670) phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 07 01; 29(7):1541-1547. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29718092) Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 09 20; 36(27):2804-2807. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29939840) Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. 10; 36(26):2736-2740. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29939838) Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29863451) Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):21-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29736741) Phase II study of selective JAK1/2 inhibitor, in patients with metastatic Cancer. 2018; 4:10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29761158) Predicting breast cancer therapeutic response. Nat Med. 2018 05; 24(5):535-537. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29736021) Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway. J 05 cancer-specific survival by age: Worse outcomes for the oldest patients. 2018 05 15; 124(10):2184-2191. View ESR1 Cancer Cell. 2018 02 12; 33(2):173-186.e5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29438694) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res. 2018 04 15; 24(8):1795-1804. for in: guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29332137) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Oncol. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29298117) Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29045519) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 12 01; 28(12):3111. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28327998) Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. Breast cancer: T-DM1 - an important agent in the history of breast cancer management. Nat Oncol. 2017 11; early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712. View in: Efficacy Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Peripheral Patients Cancer Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Cancer-Can Stop?: 3(3):402-409. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27892991) Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: guidelines for breast cancer (ABC [Breast 31 Stage Breast Cancer in Patients Treated with Neoadjuvant Systemic of Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28045625) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017 01 01; 28(1):16-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28177437) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017 Feb; 31:244-259. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27927580) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 2017 01; 161(2):363-373. View in: Perils of 2016 11 20; 34(33):3959-3962. in: Biomarker HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 11 03; 375(18):1738-1748. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27717303) Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016 Dec; 30:136-140. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27721193) Cabozantinib for of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat. 2016 11; 160(2):305-312. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27714541) Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Cancer Res Treat. 2016 11; 160(2):297-304. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27704226) Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27484879) Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. J Clin Oncol. 2016 09 20; 34(27):3308-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27480155) I-SPY More Rapid Progress in Breast Cancer Treatment. N Engl J Med. 2016 Jul 07; 375(1):83-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27406352) The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. inhibition of mice orthotopic patient-derived xenografts of HER2-positive breast 2016 07; 22(7):723-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27270588) Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27271765) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016 Jul [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27155741) Phase III Trial Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Breast View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27126994) Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016 May 01; 34(13):1460-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26976419) Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016 Mar 14; 29(3):255-269. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26977878) Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016 08 01; 22(15):3764-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26957554) Timeliness in Breast 2016 Mar; 2(3):302-4. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26658500) for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J 2016 05 10; 34(14):1689-701. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26884586) Randomized of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016 Apr 15; 122(8):1169-77. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26872302) Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26868124) Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer. Clin Cancer Res. 2016 07 01; 22(13):3249-59. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26842237) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Clin Oncol. 2016 Mar 20; 34(9):945-52. View in: Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016 Jan 21; 529(7586):413-417. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26735014) Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, PI3K dependency activation of signaling. Oncogene. 2016 06 09; 35(23):2961-70. and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. 34(6):542-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26527775) Role vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26578779) Pneumocystis neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat. 2015 Nov; 154(2):359-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26420402) Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26410082) Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26222764) Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast. 2015 Nov; 24 Suppl 2:S132-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26255198) Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist. 2015 Sep; 20(9):992-1000. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26240134) Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. J Clin Oncol. 2015 Sep 01; 33(25):2772-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26215945) In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26211600) Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26169615) Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26123926) Body Mass [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26113580) Randomized Phase III Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26056183) Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. Oncologist. 2015 Jul; 20(7):713-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26025931) Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26022349) Chemotherapy-related amenorrhea after adjuvant Res Treat. 2015 Jun; 151(3):589-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25981899) Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol. 2015 Jul 10; 33(20):2254-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25964252) the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug; 26(8):1533-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25939896) Local Therapy Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Surg Oncol. 2015 Nov; 22(12):3809-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25930247) Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Ann Surg View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25893416) II of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Jun 10; 33(17):1902-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25847936) Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; phase Ib study and MK-2206 in advanced solid tumors and metastatic breast cancer. J Cancer Inst. 2015 Mar; 107(3). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25688104) Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin 372(2):134-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25564897) Tumor-infiltrating lymphocytes and Oncol. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25559817) Personalization of loco-regional care for breast cancer 1). Future Oncol. 2015; 11(9):1297-300. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25952777) Personalization of loco-regional care breast cancer (part 2). Future Oncol. 2015; 11(9):1301-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25952778) plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast Res Treat. 2015 Jan; 149(1):151-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25537644) Reply to V. 2015 Jan 20; 33(3):291. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25512457) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25495490) Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast gemcitabine and versus gemcitabine and carboplatin with in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25349301) Trastuzumab adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 NCCTG [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25332249) ESO-ESMO 2nd international consensus guidelines for advanced breast (ABC2). Breast. 2014 Oct; 23(5):489-502. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25244983) ESO-ESMO 2nd international consensus guidelines advanced breast (ABC2). Ann Oncol. 2014 Oct; for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. View US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-2217. View in: Breast Cancer. 2015 Feb; 15(1):24-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25205424) Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer. 2014 Oct 14; 111(8):1532-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25101563) Impact of and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25092775) Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66. View Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24934787) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance J Cancer Surviv. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. Clin Breast Cancer. 2014 Dec; 14(6):413-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24970714) Circulating tumor cells and response in metastatic breast cancer: SWOG [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24888818) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24888816) Adjuvant with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24881463) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24868023) Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014 Aug; 25(8):1656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24827126) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2078-99. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24799465) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2100-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24799487) Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24756187) Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia. Leukemia. 2014 Nov; 28(11):2165-77. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24699303) Male breast cancer networking and telephone support group: a model for supporting a unique population. Psychooncology. 2014 Aug; 23(8):956-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24700635) Stand buparlisib 2014 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24663045) Defining success in neoadjuvant breast Lancet. 2014 Jul 12; 384(9938):115-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24529559) Polygenic inheritance of paclitaxel-induced sensory driven axon outgrowth gene sets in CALGB Pharmacogenomics J. 2014 Aug; 14(4):336-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24513692) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based 20; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24516021) A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. Cancer Med. 2014 Apr; 3(2):293-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24464780) Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Jan; 12(1):71-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24453294) Breast cancer presentation and diagnostic delays in young women. Cancer. 2014 Jan 01; 120(1):20-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24347383) A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24197661) Reply to P.G. Tsoutsou et al, o. Kaidar-Person et al, and A. Courdi et al. J Res. 2014 Jan 01; 20(1):15-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24135146) Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24113744) Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24062210) Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med. 2013 Sep 17; 159(6):373-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24042365) Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction. Breast Cancer Res Treat. 2013 Sep; 141(2):255-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24026859) Long-term cardiac safety and outcomes dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Nov 15; 119(22):3943-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24037735) Pertuzumab: 19(20):5552-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23942091) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9):2206-23. View in: 3(8):832. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23928759) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. Aug; 13(4):254-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23829891) I dose-escalation VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer. Breast Cancer Res Treat. 2013 Jul; 140(2):331-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23868188) A Phase 1 trial of the poly(ADP-ribose) polymerase olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23810467) A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24472479) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. Oncol. Jul 20; 31(21):2692-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23752109) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23690420) Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat. 2013 Jun; 139(2):607-16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23681403) Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res. 2013 Oct; 48(5):1669-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23663229) A phase II study of in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23645007) International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013 Jun; 22(3):203-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23601761) Long-term risk perceptions of women carcinoma in situ. Oncologist. 2013; 18(4):362-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23568001) and trastuzumab metastatic HER2-positive View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23559151) Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013 Jul; 24(7):1853-1859. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23493137) PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):457-66. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23423445) Male breast cancer: risk factors, diagnosis, treatment, survivorship. Ann Oncol. 2013 Jun; 24(6):1434-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23425944) High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23349386) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23352568) Quality of life and symptoms in male breast cancer survivors. Breast. 2013 Apr; 22(2):197-199. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23313328) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Jan View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23204130) Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Res Treat. 2012 Dec; 136(3):919-26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23143284) Body image in recently diagnosed young women with early breast cancer. Psychooncology. 2013 Aug; 22(8):1849-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23132765) Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012 Dec; 136(3):813-21. View in: Human epidermal growth factor receptor-2-positive cancer: does estrogen receptor status define two 2013 Feb; 24(2):283-291. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23022997) Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with Treat. 2012 Nov; 136(1):169-78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23001754) Survival implications associated with variation in mastectomy rates for early-staged breast cancer. Int J Surg Oncol. 2012; 2012:127854. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22928097) Park). 2012 Aug; 26(8):688-94, in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22957400) Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice? J Clin Oncol. 2012 Sep A genome-wide study identifies sensory peripheral neuropathy in CALGB Sep 15; 18(18):5099-109. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22843789) Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis. Cancer. 2013 Jan 15; 119(2):250-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22833148) Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. Nov 20; 30(33):4071-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22826271) Psychosexual functioning and body image following a diagnosis of ductal carcinoma in situ. J Sex Med. 2013 in: 20; 30(24):2940-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22802318) Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat. 2012 Aug; 134(3):1305-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22791365) Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul 20; 30(21):2615-23. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22665533) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, an anthracycline, a 30(26):3234-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22649126) Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract. 2012 Sep; 8(5):e105-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23277772) Choosing regimen: should abandon anthracyclines? 2012 Jun 20; 30(18):2179-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22614986) The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012; 17(6):775-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22554997) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15; 118(22):5463-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22544643) Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer. 2012 Apr; 12(2):119-26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22444718) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22425534) A (BIBW 2992), irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22418700) The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol. 2012 Mar 01; 30(7):690-1. in: 2012 Jan; 13(1):2-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22225715) A dickens tale of the treatment of advanced breast cancer: the past, the present, and the future. Am Soc Clin Oncol Educ Book. 2012; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22162585) Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012 Feb; 131(3):1061-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22080245) Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22017599) Adjuvant chemotherapy in luminal breast Breast. 2011 Oct; 20 Suppl 3:S128-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22015279) Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21934103) Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(2):589-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21881937) Should a sentinel node biopsy be performed in patients with high-risk breast cancer? Int J Breast Cancer. 2011; 2011:973245. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22295240) The ethical use of mandatory research biopsies. Nat Rev Clin Oncol. 2011 08 02; 8(10):620-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21808265) American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. J Clin Oncol. 2011 Oct 01; 29(28):3816-24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21810680) Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1075-80. View in: with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. 2011 Aug 10; 29(23):3126-32. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21730275) Feb; 23(2):305-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21715566) capecitabine or lapatinib plus topotecan for patients with breast J Neurooncol. 2011 Dec; 105(3):613-20. of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and Clin Breast Cancer. 2011 Dec; 11(6):376-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21697017) p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21693655) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21531783) Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol. 2011 Oct; 18(10):2885-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21431404) GPHMM: hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin 15; 17(10):3490-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21372222) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21324674) Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol. 2011 Mar 10; 29(8):1022-8. View in: Chemotherapy in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol. 2011 Jan 20; 29(3):251-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21149664) The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011 Jan 01; 117(1):180-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20939011) 01; reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010 Sep-Oct; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20581724) Cardiac toxicity from systemic cancer a comprehensive Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20728696) Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer. J Womens Health (Larchmt). 2010 Aug; 19(8):1553-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20629579) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20625130) Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010 Jul 07; 102(13):942-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20554945) Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol. 2010 trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20479410) Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat. 2011 Feb; 125(3):803-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20376555) Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 10; 28(14):2418-22. View for management of metastatic breast cancer: can metastatic breast cancer be cured? 2010 Apr 07; 102(7):456-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20220104) The role of socioeconomic status in adjustment after ductal carcinoma in situ. Cancer. 2010 Mar 01; 116(5):1218-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20143325) Efficacy 28(7):1145-53. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20100965) Adjuvant therapy for postmenopausal women Breast. 2010 Apr; 19(2):69-75. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20034796) Prognostic and predictive value of recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20005174) Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women. Breast Cancer Res Treat. 2010 Jun; 121(3):743-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19949856) On mammography--more agreement than disagreement. Dec 361(26):2499-501. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19940286) Dose-dense adjuvant Doxorubicin and cyclophosphamide not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19901120) Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Dec 10; 27(35):6052-69. View in: Refining for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19884535) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009 Oct; 133(10):1515-38. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19792042) International guidelines for management of breast cancer: combination vs sequential single-agent chemotherapy. Sep 02; 101(17):1174-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19657108) Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care. 2009 Jul; 47(7):765-73. View in: doxorubicin, and fluorouracil therapy in HER2-amplified CALGB 27(21):3430-6. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19470942) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19439741) Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control. 2009 Oct; 20(8):1523-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19434504) Phase I study plus trastuzumab in patients with HER2-positive Cancer. 2009 May; 9(2):101-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19433391) Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 117(3):615-23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19294501) ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009 Feb 27; 2:11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19250532) Multicenter II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009 Feb 15; 15(4):1452-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19228746) Breast cancer. of exemestane versus anastrozole in patients with postmenopausal breast cancer with Breast Cancer. 2009 Feb; 9(1):39-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19299239) Sharing study results with trial participants: time for action. J Clin Oncol. 2009 Feb 20; 27(6):838-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19164202) Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med. 2009 Jan; 133(1):15-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19123730) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009 Feb 10; 27(5):713-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19103731) Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Oncol. cancer: risk factors potential targets. Res. 2008 Dec 15; 14(24):8010-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19088017) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19047116) Reducing disparities in breast cancer care: a daunting but essential responsibility. J Natl Cancer Inst. 2008 Dec 03; 100(23):1661-3. View in: practices Clin Oncol. 2008 Dec 20; 26(36):5994-6000. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19029413) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15; 113(10):2638-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18833576) Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: 79804. Psychooncology. 2008 Nov; 17(11):1108-20. View in: activity women diagnosed The optimal duration of surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18581232) The impact of sharing results of a randomized breast cancer clinical trial with study participants. Breast Cancer Res Treat. 2009 May; 115(1):123-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18543100) Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B. 2008 Jun 01; 26(16):2659-65. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18509177) Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer. 2008 Jun; 8(3):275-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18650159) Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18496750) Ten years of HER2-directed therapy: still questions after all these years. Breast Cancer Res Treat. 2009 Jan; 113(2):207-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18463974) Pharmacogenomic variation of CYP2D6 of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Cancer Inst. 2008 May 07; 100(9):642-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18445827) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin axillary surgery in early-stage breast cancer: results of a prospective trial. Int J trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol. 2008 Apr 20; 26(12):1919-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18332468) Ten-year and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008 Mar-Apr; median follow-up results followed mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944). Breast Cancer Res Treat. 2009 Feb; 113(3):479-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18306034) Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008 Feb 20; 26(6):907-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18281663) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst. 2008 Feb 20; 100(4):243-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18270338) endocrine in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18258991) Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions. J Clin Oncol. 2008 Feb 10; 26(5):696-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18258975) analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 26(8):1231-8. View aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer. 2008 Feb 01; 112(3 Suppl):700-709. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18072256) Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference. Cancer. 2008 Feb 01; 112(3 Suppl):673-678. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18072254) Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer. 2008 Feb; 8(1):65-9. View in: and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18234424) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J 2008 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18180462) NCCN Task Force Report: Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer. 2008; 15(1):31-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18224391) Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18086794) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology. 2007 Dec; 245(3):824-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17954616) Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med. 2007 Oct 18; 357(16):1640-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17942877) Care in the months before death and hospice enrollment among older women with advanced breast cancer. J Gen Intern Med. 2008 Jan; 23(1):11-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17939006) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18021484) Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 Oct; 16(10):895-903. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17245695) Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health. Sep-Oct; 10(5):367-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17888101) Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep the 2007 Sep 01; 110(5):965-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17614302) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17704418) Follow-up care of patients with Dec; 16 Suppl 2:S45-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17697780) Jul 01; 25(19):2639-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17563391) Local therapy and survival in breast cancer. N Engl J Med. 2007 Jun 07; 356(23):2399-405. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17554121) View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17266054) Erratum: Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psychooncology. 2007 May 24; 16(10). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17525937) Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007 Jul; 43(11):1646-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17512721) Implementing an interdisciplinary governance model in a comprehensive cancer center. Oncol Nurs Forum. 2007 May; 34(3):611-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17573318) Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer. 2007 Apr 01; 109(7):1239-46. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17326054) Surveillance testing among survivors of breast cancer. Clin Oncol. 2007 Mar 15; 13(6):1648-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17363517) Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75. View vinorelbine for HER2-positive early breast cancer. Res. 2007 Feb 15; 13(4):1198-207. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17317830) Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ. 2007; 22(1):21-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17570804) Pneumocystis Oncol. 2006 Nov 20; 24(33):5330-1. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17114668) Virtual Reality Exposure Therapy for PTSD symptoms after a road accident: an uncontrolled case Ther. 2007 Mar; 38(1):39-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17292693) Menopausal-type Dec; 17(12):1777-82. View a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16969707) Cancer-related communication between female patients and male partners scale: A pilot study. Psychooncology. 2006 Sep; HER2 testing in in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16813731) The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Jun 15; 106(12):2576-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16703595) Interleukin-6, multidrug resistance protein-1 expression response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806. Breast Cancer Res Treat. 2006 Dec; 100(3):301-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16773437) Acute lymphoblastic leukemia with by multi-modal strategy of conventional cytogenetics, FISH, morphology, flow cytometry and molecular genetics, and review of the Exp Mol Pathol. 2006 Aug; 81(1):62-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16765346) Cancer and leukemia group B breast committee: decades of progress and plans for the future. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3576s-80s. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16740788) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16609087) NCCN Task [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16507275) Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):997s-1000s. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16467115) Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early stage breast cancer. Womens Health (Lond). 2006 Jan; 2(1):89-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19803930) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17129383) Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol. 2006 Jan 01; 24(1):85-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16382117) Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med message? Cancer Inst. 97(23):1712-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16333021) Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16288876) Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. 20; 23(33):8340-7. View as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. Breast Cancer Res. 2005; 7(6):255-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16457700) Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16243442) Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006 Oct; 63(1-2):104-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16242898) Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005 Oct 15; 104(8):1580-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16118805) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 23(30):7703-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16157938) Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16150805) Ovarian suppression for breast cancer: an effective treatment in search of a home. J Clin Oncol. 2005 Sep 01; 23(25):5869-72. View in: therapy in postmenopausal women with early-stage breast cancer: a decision analysis. Oncol. 2005 breast cancer survivorship: CALGB study 79804. Breast Cancer Res Treat. 2005 May; 91(2):153-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15868443) Fertility after breast 2005 Mar 10; 23(8):1609-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15755964) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15741529) Offering participants results of a clinical trial: sharing results of a negative study. Lancet. 2005 Mar 12-18; 365(9463):963-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15766998) HER2 or not HER2: Oncol. 2005 Jun 01; 23(16):3656-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15738533) Patient utilities for advanced cancer: effect of current health on values. Med Care. 2005 Feb; 43(2):173-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15655431) Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat 01; 61(2):348-57. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15667952) The association of ambulatory care with breast cancer stage at diagnosis among Medicare beneficiaries. J Gen Intern Med. 2005 Jan; 20(1):38-44. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15693926) The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. 20; 23(3):619-29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15545664) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 Oct 15; 22(20):4174-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15483028) Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7. View 01; 22(17):3608-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15337811) New for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15318926) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. 2004 Jun 01; 22(11):2061-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15169793) Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32. 01; 22(5):854-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14990641) Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 2004; 21:55-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15687723) Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer. J Clin Oncol. 2003 Dec 15; 21(24):4532-9. breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12885806) Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003 Jul-Aug; 12(5):410-27. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12833555) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7. View in: troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12846423) American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12732612) Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12697865) The aromatase inhibitors as adjuvant hormone cancer. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19768880) Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12644548) Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12637463) Phase randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12637464) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003 Feb 15; 21(4):602-6. View in: of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9. Clinical the Jan; adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12506169) cancer. Oncology. 2003; 64(4):289-99. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12759523) Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12538498) Complementary and alternative medicine use among women with breast cancer. J Clin Oncol. 2002 Sep 15; Oncol. 2002 Sep 01; 20(17):3576-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12202656) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12149306) American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, aromatase View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12149307) Informing clinical trial participants about results. JAMA. 2002 Jul 17; 288(3):363-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12117402) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 agents. J multicenter trial as first-line therapy of metastatic breast 2002 Jan 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11815957) Pre-counseling education Semin Oncol. 2001 Aug; 28(4):344-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11498829) Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):589-98. Clinical of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001 trastuzumab and women with HER2-overexpressing metastatic breast 2001 May 15; 19(10):2722-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11352965) Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001 May 01; 19(9):2381-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11331316) Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001; 14:41-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15687635) New combinations 61 Suppl 2:50-7. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11694788) Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. 2000 Nov; 14(11A):33-49. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11195418) Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11027744) Use of taxanes in the treatment of patients with breast cancer has increased dramatically over the past 8 years. Clin Breast Cancer. 2000 Jul; 1(2):164-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11899655) Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000 Jul; 18(14):2710-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10894870) Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2. J Genet Couns. 2000 Jun; 9(3):219-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26141318) Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg. 2000 May; 231(5):624-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10767783) Docetaxel administered on weekly metastatic J Clin Oncol. 2000 Mar; 18(6):1212-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10715290) Involving family members in cancer care: focus group considerations of patients and oncological providers. Psychooncology. 2000 Mar-Apr; 9(2):101-12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10767748) A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer. 2000 Feb 15; 88(4):825-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10679652) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 Doxil in in: Hydrocortisone mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999 Aug; 17(8):2506-13. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10561316) Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Group 17(5):1397-406. View node dissection indicated for early-stage breast cancer? A decision analysis. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10334532) Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999 Apr; 10(4):397-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10370781) Assessing 01; 44(1):91-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10219800) Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10071299) Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support. Psychooncology. 1999 Mar-Apr; 8(2):167-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10335560) Randomized phase III potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol. 1999 Jan; 17(1):52-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10458218) Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic cancer. Cancer 43(1):68-72. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9923543) Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey. Cancer. 1998 Oct 01; 83(7):1362-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9762937) Oral 5-FU analogues in Oct; breast-ovarian cancer susceptibility genes: a decision 1998 Oct-Dec; 18(4):365-75. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/10372578) Overestimation Surg. Sep; 228(3):375-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9742920) An integrated genetic Mamm Genome. 1998 Jul; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9657848) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998 Jul; 16(7):2417-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9667259) Cancer pain survey: patient-centered issues in control. J Pain Symptom Manage. 1998 May; 15(5):275-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9654832) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998 Apr; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9552041) Informed Breast Dis. 1998 Apr; 10(1-2):99-114. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15687553) Genetic testing for susceptibility to breast cancer: findings from women's focus groups. J Womens Health. 1997 Jun; 6(3):317-27. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9201666) Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr. 1997 May; 65(5):1495-501. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9129482) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc. 1997 May; 97(5):519-26, 529; quiz 527-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9145091) A review of hereditary breast cancer: from screening to risk factor modification. Am J Med. 1997 Apr; 102(4):407-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9217624) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Inst. 1997 Feb 05; 89(3):227-38. retinoic acid in metastatic breast cancer: a Chemother Pharmacol. 1997; 40(4):335-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9225952) Factors contributing to patient satisfaction with breast reconstruction using silicone gel implants. Plast Reconstr Surg. 1996 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/9229318) Cloning, characterization, and genetic mapping of the rat type 2 angiotensin II receptor gene. Hypertension. 1995 Dec; 26(6 Pt 1995 Oct; 13(10):2567-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/7595708) Use of simple sequence length polymorphisms for genetic characterization of rat inbred strains. Mamm Genome. 1995 Sep; of heterozygosity scores and polymorphism information content values for rat genetic markers. Mamm Aug; 6(8):512-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8589519) Oral feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol. 1994 Sep; 12(9):1754-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8083697) Quality-of-life research with Cancer. 1994 Jul 01; 74(1 Suppl):410-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8004614) Quality of life transplantation. Oncology (Williston Park). 1994 Jan; 8(1):19-27; discussion 27-8, 31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8123445) Silicone controversy: a survey of women with breast cancer and silicone implants. J Natl Cancer Inst. 1993 Sep 01; 85(17):1407-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8350364) Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993 Jul; 11(7):1418-29. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/8315439) High-dose autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin 1993 Jun; phase trial in combination with vinblastine. J Inst. using streptozotocin: phase I trial. Cancer Res. 1992 May 01; 52(9):2456-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/1533174) Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/2211201) The use of adjuvant chemotherapy for breast cancer in a community practice. Conn Med. 1985 "}